Cora Schlesinger
Growth, contrarian, long only

GTx Inc.: Recent Market Action

GTx: Enobosarm trials

GTx Inc. (NASDAQ:GTXI) is a Memphis-based microcap biopharmaceutical company that has a large pipeline of Selective Androgen Response Modifiers (SARMs), which are androgen (male hormone) analogues. GTx has just completed two Phase III (P3) clinical trials of its lead drug, enobosarm, called POWER 1 and POWER 2. A "data lock" was placed in May, allowing the data to be analyzed. The two primary endpoints of the enobosarm POWER trials were to stabilize or improve lean body muscle (LBM) wasting (sarcopenia); and physical function (strength), in patients with advanced, Stage 3/4, non-small cell lung cancer (NSCLC). Muscle loss occurs very early in the cancer process, and, in fact, it is broken down preferentially over fat,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details